Expansion of SARS-CoV-2-specific Antibody-secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients
Renata Varnaitė,Marina García,Hedvig Glans,Hedvig Glans,Kimia T Maleki,John Tyler Sandberg,Janne Tynell,Wanda Christ,Nina Lagerqvist,Hilmir Asgeirsson,Hilmir Asgeirsson,Hans-Gustaf Ljunggren,Gustaf Ahlén,Lars Frelin,Matti Sällberg,Kim Blom,Jonas Klingström,Jonas Klingström,Sara Gredmark-Russ,Sara Gredmark-Russ +19 more
Reads0
Chats0
TLDR
This study observed a significant expansion of SARS-CoV-2 nucleocapsid protein-specific ASCs in all twenty COVID-19 patients using a multicolor FluoroSpot assay, and found that Sars-Cov-2-specific IgA, IgG and IgM antibody levels positively correlated with SARS -CoV -2-neutralizing antibody titers.Abstract:
COVID-19, caused by SARS-CoV-2, emerged in late 2019 and has since become a global pandemic. Pathogen-specific antibodies are typically a major predictor of protective immunity, yet B cell and antibody responses during COVID-19 are not fully understood. Here, we analyzed antibody-secreting cell (ASC) and antibody responses in twenty hospitalized COVID-19 patients. We observed a significant expansion of SARS-CoV-2 nucleocapsid protein-specific ASCs in all twenty COVID-19 patients using a multicolor FluoroSpot assay. Out of the 20 patients, 16 had developed SARS-CoV-2-neutralizing antibodies by the time of sampling. Additionally, we found that SARS-CoV-2-specific IgA, IgG and IgM antibody levels positively correlated with SARS-CoV-2-neutralizing antibody titers. This study constitutes a detailed description of B cell and antibody responses to SARS-CoV-2 in COVID-19, and provides tools to study immune responses to SARS-CoV-2 infection and vaccination.read more
Citations
More filters
Posted ContentDOI
Antibody response to SARS-CoV-2 infection in humans: a systematic review
Nathan Post,Danielle Eddy,Catherine Huntley,May C I van Schalkwyk,Madhumita Shrotri,David Leeman,Samuel Rigby,Sarah V. Williams,William H. Bermingham,Paul Kellam,John Maher,Adrian M Shields,Gayatri Amirthalingam,Sharon J. Peacock,Sharif Ismail +14 more
TL;DR: In this paper, a systematic review comprehensively evaluated evidence describing the antibody response to SARS-CoV-2 published from 1/01/2020-26/06/2020.
Journal ArticleDOI
Laboratory diagnosis of coronavirus disease-2019 (COVID-19).
TL;DR: This review will discuss the performance of different laboratory diagnostic tests and platforms, as well as suitable clinical samples for testing, and related biosafety protection, for the diagnosis of COVID-19 caused by SARS-CoV-2.
Journal ArticleDOI
Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination
Chengzi I. Kaku,Elizabeth Champney,Johan Normark,Marina García,Carl Johnson,Clas Ahlm,Wanda Christ,Mrunal Sakharkar,Margaret E. Ackerman,Jonas Klingström,Mattias N. E. Forsell,Laura M. Walker +11 more
TL;DR: The results provide molecular insight into the enhanced quality of the B cell response induced after heterologous mRNA booster vaccination, and examine the immunity induced by either prime and boost with the adenoviral vectored vaccine ChAd Ox1 or prime with ChAdOx1 andBoost with a messenger RNA (mRNA) vaccine.
Journal ArticleDOI
SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments.
Gisela Canedo-Marroquín,Farides Saavedra,Catalina A. Andrade,Roslye V Berrios,Linmar Rodríguez-Guilarte,Maria Cecilia Opazo,Claudia A. Riedel,Alexis M. Kalergis +7 more
TL;DR: Clinical evidence suggests that migration of immune cells to the affected organs can produce an exacerbated release of proinflammatory mediators that contribute to disease and render the immune response as a major player during the development of the COVID-19 disease.
Journal ArticleDOI
Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials
S. C. Thuluva,Vikram M. Paradkar,S. Gunneri,V. Yerroju,R. Mogulla,K. Turaga,Mahesh Kyasani,Senthil Kumar Manoharan,Guruprasad R. Medigeshi,J. Singh,Heena Shaman,Chandramani Singh,Venkateshwar Rao A +12 more
TL;DR: A randomised Phase-1/2 trial followed by a Phase-2 trial were conducted to assess the safety and immunogenicity of the COVID-19 vaccine Corbevax and select to an optimum formulation as discussed by the authors .
References
More filters
Journal ArticleDOI
Human Ebola virus infection results in substantial immune activation
Anita K. McElroy,Rama Akondy,Carl W. Davis,Ali H. Ellebedy,Aneesh K. Mehta,Colleen S. Kraft,G. Marshall Lyon,Bruce S. Ribner,Jay B. Varkey,John Sidney,Alessandro Sette,Shelley Campbell,Ute Ströher,Inger K. Damon,Stuart T. Nichol,Christina F. Spiropoulou,Rafi Ahmed +16 more
TL;DR: Sustained immune activation after the virus was cleared from the plasma is found, observed most strikingly in the persistence of activated CD8 T cells, even 1 mo after the patients’ discharge from the hospital, suggesting continued antigen stimulation after resolution of the disease.
Journal ArticleDOI
Blood-borne human plasma cells in steady state are derived from mucosal immune responses
Henrik E. Mei,Taketoshi Yoshida,Wondossen Sime,Falk Hiepe,Kathi Thiele,Rudolf A. Manz,Andreas Radbruch,Thomas Dörner +7 more
TL;DR: It is shown that plasmablasts and plasma cells are always detectable in human blood at low frequency in any unimmunized donor, indicating that mucosal and systemic humoral immune responses are regulated independent of each other.
Journal ArticleDOI
Elucidation of seventeen human peripheral blood B-cell subsets and quantification of the tetanus response using a density-based method for the automated identification of cell populations in multidimensional flow cytometry data
Yu Qian,Chungwen Wei,F. Eun-Hyung Lee,John D.M. Campbell,Jessica L. Halliley,Jamie A. Lee,Jennifer Cai,Y. Megan Kong,Eva L. Sadat,Elizabeth Thomson,Patrick Dunn,Adam C. Seegmiller,Nitin J. Karandikar,Christopher M. Tipton,Tim R. Mosmann,Iñaki Sanz,Richard H. Scheuermann +16 more
TL;DR: Advances in multiparameter flow cytometry now allow for the independent detection of larger numbers of fluorochromes on individual cells, generating data with increasingly higher dimensionality.
Journal ArticleDOI
Rapid and massive virus specific plasmablast responses during acute dengue virus infection in humans
Jens Wrammert,Nattawat Onlamoon,Rama Akondy,Guey Chuen Perng,Korakot Polsrila,Anmol Chandele,Marcin Kwissa,Bali Pulendran,Patrick C. Wilson,Orasri Wittawatmongkol,Sutee Yoksan,Nasikarn Angkasekwinai,Kovit Pattanapanyasat,Kulkanya Chokephaibulkit,Rafi Ahmed +14 more
TL;DR: Very potent plasmablast responses that often increased more than 1,000-fold over the baseline levels in healthy volunteers are found, raising the question as to whether these cells might have a role in dengue immunopathology during the ongoing infection.
Journal ArticleDOI
Origin and Function of Circulating Plasmablasts during Acute Viral Infections
TL;DR: This review summarizes what is known about the phenotype and the origin of human plasmablasts in the context of viral infections and whether these cells can be predictors of long-lived immunity.
Related Papers (5)
Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients
Christoph Kreer,Matthias Zehner,Timm Weber,Cornelius Rohde,Sandro Halwe,Meryem S. Ercanoglu,Lutz Gieselmann,M. Korenkov,Henning Gruell,Philipp Schommers,Kanika Vanshylla,Veronica Di Cristanziano,Hanna Janicki,Reinhild Brinker,Artem Ashurov,Verena Krähling,Alexandra Kupke,Hadas Cohen-Dvashi,Manuel Koch,Simone Lederer,Nico Pfeifer,Timo Wolf,Maria J G T Vehreschild,Clemens M. Wendtner,Ron Diskin,Stephan Becker,Florian Klein +26 more
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Yiska Weisblum,Fabian Schmidt,Fengwen Zhang,Justin DaSilva,Daniel Poston,Julio C. C. Lorenzi,Frauke Muecksch,Magdalena Rutkowska,Hans-Heinrich Hoffmann,Eleftherios Michailidis,Christian Gaebler,Marianna Agudelo,Alice Cho,Zijun Wang,Anna Gazumyan,Melissa Cipolla,Larry L. Luchsinger,Christopher D. Hillyer,Marina Caskey,Davide F. Robbiani,Davide F. Robbiani,Charles M. Rice,Michel C. Nussenzweig,Michel C. Nussenzweig,Theodora Hatziioannou,Paul D. Bieniasz,Paul D. Bieniasz +26 more
A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model.
Jakob Kreye,S. Momsen Reincke,Hans Christian Kornau,Hans Christian Kornau,Elisa Sanchez-Sendin,Elisa Sanchez-Sendin,Elisa Sanchez-Sendin,Victor M. Corman,Hejun Liu,Meng Yuan,Nicholas C. Wu,Xueyong Zhu,Chang-Chun D Lee,Jakob Trimpert,Markus Höltje,Kristina Dietert,Laura Stöffler,Laura Stöffler,Niels von Wardenburg,Niels von Wardenburg,Scott van Hoof,Scott van Hoof,Scott van Hoof,Marie A Homeyer,Marie A Homeyer,Julius Hoffmann,Julius Hoffmann,Azza Abdelgawad,Achim D. Gruber,Luca D. Bertzbach,Daria Vladimirova,Lucie Y Li,Lucie Y Li,Paula Charlotte Barthel,Karl Skriner,Andreas C. Hocke,Stefan Hippenstiel,Martin Witzenrath,Norbert Suttorp,Florian Kurth,Florian Kurth,Christiana Franke,Matthias Endres,Dietmar Schmitz,Dietmar Schmitz,Lara Maria Jeworowski,Anja Richter,Marie Luisa Schmidt,Tatjana Schwarz,Marcel A. Müller,Christian Drosten,Daniel Wendisch,Leif E. Sander,Nikolaus Osterrieder,Nikolaus Osterrieder,Ian A. Wilson,Harald Prüss,Harald Prüss,Harald Prüss +58 more
Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants.
Saya Moriyama,Yu Adachi,Takashi Sato,Keisuke Tonouchi,Lin Sun,Shuetsu Fukushi,Souichi Yamada,Hitomi Kinoshita,Kiyoko Nojima,Takayuki Kanno,Minoru Tobiume,Keita Ishijima,Yudai Kuroda,Eun-Sil Park,Taishi Onodera,Takayuki Matsumura,Tomohiro Takano,Kazutaka Terahara,Masanori Isogawa,Ayae Nishiyama,Ai Kawana-Tachikawa,Masaharu Shinkai,Natsuo Tachikawa,Shigeki Nakamura,Takahiro Okai,Kazu Okuma,Tetsuro Matano,Tsuguto Fujimoto,Ken Maeda,Makoto Ohnishi,Takaji Wakita,Tadaki Suzuki,Yoshimasa Takahashi +32 more